Retatrutide dosage for weight loss is a subject of growing clinical interest, as this investigational triple receptor agonist has demonstrated substantial body weight reductions in Phase 2 trials. Developed by Eli Lilly, retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors — a mechanism that distinguishes it from approved agents such as semaglutide and tirzepatide. Trial dosing follows a stepwise escalation from 1–2 mg up to maintenance doses of 4 mg, 8 mg, or 12 mg subcutaneously once weekly. Retatrutide is not yet approved by the MHRA and remains available only within authorised clinical research settings in the UK.

What Is Retatrutide and How Does It Support Weight Loss?

Retatrutide supports weight loss by simultaneously activating GLP-1, GIP, and glucagon receptors, reducing appetite and increasing energy expenditure. Phase 2 trial data showed a mean body weight reduction of approximately 24% at the 12 mg weekly maintenance dose over 48 weeks.

Retatrutide is an investigational injectable medication currently under clinical development for the treatment of obesity and overweight. It belongs to a novel class of agents known as triple receptor agonists, meaning it simultaneously activates three distinct hormone receptors:

• GLP-1 (glucagon-like peptide-1) — which reduces appetite and slows gastric emptying^[7][8]

• GIP (glucose-dependent insulinotropic polypeptide) — which is hypothesised to enhance insulin secretion and may play a role in fat metabolism, though the precise contribution remains under investigation

• Glucagon receptor — which is thought to increase energy expenditure and promote hepatic fat breakdown, though these mechanisms are still being characterised in human studies^[9][10]

This triple mechanism distinguishes retatrutide from existing approved agents such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GLP-1/GIP agonist), and is thought to produce more pronounced effects on body weight.^[7][11]

In a Phase 2 randomised controlled trial published in The New England Journal of Medicine (Jastreboff et al., 2023), retatrutide demonstrated substantial reductions in body weight over 48 weeks. Participants receiving the highest maintenance dose (12 mg once weekly) achieved a mean body weight reduction of approximately 24% from baseline in those without type 2 diabetes — a notably larger effect than that observed with currently approved agents in comparable timeframes.

Regarding retatrutide dosage for weight loss, the Phase 2 trial used a dose-escalation approach across several cohorts. Participants were started on lower doses — typically 1 mg or 2 mg subcutaneously once weekly — and gradually titrated upward over multiple weeks to maintenance doses of 4 mg, 8 mg, or 12 mg administered subcutaneously once weekly. Different titration pathways were used across cohorts. This stepwise escalation is designed to improve tolerability, particularly in relation to gastrointestinal side effects.

It is important to note that all dosing regimens described here are investigational. Retatrutide does not have an approved posology and has not been authorised for clinical use in the UK or elsewhere.

Who May Be Suitable for Retatrutide in the UK?

Outside clinical trials, no approved UK patient population exists for retatrutide. Trial eligibility has included adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with a weight-related comorbidity such as type 2 diabetes or hypertension.

As retatrutide has not yet received regulatory approval in the UK, there is currently no formally defined patient population for its use outside of clinical trials. The criteria below reflect eligibility used in Phase 2 and ongoing Phase 3 clinical studies only and should not be interpreted as future UK licensing or NHS commissioning criteria.

Based on trial eligibility, retatrutide is being investigated in adults who broadly meet the following criteria:

• BMI of 30 kg/m² or above (classified as obese), or

• BMI of 27 kg/m² or above with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidaemia

• Adults who have not achieved adequate weight loss through lifestyle interventions alone

Retatrutide trials to date have enrolled adults only; the medicine has not been studied in individuals under 18 years of age.

For context, NICE guidance on obesity pharmacotherapy — including TA875 (semaglutide for weight management) and TA924 (tirzepatide for managing overweight and obesity) — provides a useful framework for understanding how future agents might be positioned in the UK.^[13] NICE typically recommends pharmacological treatment as an adjunct to a reduced-calorie diet and increased physical activity, and applies specific BMI thresholds, including lower thresholds for certain ethnic groups at higher metabolic risk. Future NICE evaluation of retatrutide, if approved, would follow a similar process.

Certain individuals would likely be excluded from clinical trials involving retatrutide based on current trial protocols. These are trial-based exclusions and do not constitute established contraindications prior to MHRA authorisation:

• A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

• Severe gastrointestinal disorders such as gastroparesis

• Pregnancy or breastfeeding

• Significant renal or hepatic impairment (pending further safety data)

UK patients interested in accessing retatrutide through a clinical trial should speak with their GP or a specialist obesity service. GPs can refer patients to tier 3 or tier 4 specialist weight management services, and the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) provides a searchable database of UK clinical trials, including those in obesity and metabolic disease. Self-prescribing or obtaining retatrutide from unregulated online sources carries serious safety risks and must be avoided.

Possible Side Effects and Safety Considerations

The most common side effects are gastrointestinal, including nausea, vomiting, and diarrhoea, typically occurring during dose escalation. Glucagon receptor activity may raise resting heart rate, and patients should seek prompt medical advice for severe abdominal pain, biliary symptoms, or signs of dehydration.

As with other incretin-based therapies, the most commonly reported side effects of retatrutide in clinical trials are gastrointestinal in nature. These include:

• Nausea (the most frequently reported adverse effect)

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite (which, while contributing to weight loss, can occasionally be excessive)

These effects were generally mild to moderate in severity and occurred most frequently during the dose-escalation phase. The gradual titration schedule — starting at low doses and increasing incrementally over several weeks — is specifically designed to minimise gastrointestinal effects and improve tolerability.

Cardiovascular effects — heart rate The glucagon receptor agonism component of retatrutide is not present in currently approved agents. Glucagon activation can increase heart rate; Phase 2 trial data reported a mean increase in resting heart rate of approximately 4–5 beats per minute at higher doses, with some individual variation.^[1][2] This warrants careful monitoring, particularly in individuals with pre-existing cardiovascular conditions. Patients should inform their healthcare provider if they experience palpitations, dizziness, or an unusually rapid heartbeat.

Gallbladder and biliary events Gallbladder-related events, including cholelithiasis (gallstones), have been observed with GLP-1–based therapies and are also associated with rapid weight loss more broadly.^[11][12] Whilst retatrutide-specific causality data are still accumulating, patients should be aware of potential biliary symptoms. Seek prompt medical attention if you experience pain in the upper right abdomen, pain radiating to the shoulder, yellowing of the skin or eyes (jaundice), or fever alongside abdominal pain.

Dehydration and kidney function Persistent vomiting or diarrhoea can lead to dehydration, which may in turn affect kidney function. Patients should maintain adequate fluid intake and seek medical advice if they notice significantly reduced urine output, dizziness on standing, or other signs of dehydration.

Thyroid considerations Animal studies with GLP-1 class agents have raised questions about thyroid C-cell tumours, which is why individuals with a history of medullary thyroid carcinoma or MEN2 are excluded from trials.^[6][7] The clinical relevance in humans remains uncertain.

Pancreatitis As with GLP-1 receptor agonists more broadly, there are potential concerns regarding pancreatitis. Patients should seek prompt medical advice if they experience severe or persistent abdominal pain.

Contraception and pregnancy Women of childbearing potential participating in retatrutide trials should use effective contraception throughout. If pregnancy occurs during trial participation, the trial team must be notified immediately.

Reporting side effects Anyone who suspects they have experienced a side effect from a medicine or investigational product in the UK should report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app. This applies to participants in clinical trials as well as users of licensed medicines.

Current Availability and Regulatory Status in the UK

Retatrutide is not approved by the MHRA and cannot be legally prescribed in the UK outside authorised clinical trials. Approved weight management options currently available on the NHS include orlistat, semaglutide (Wegovy®), and tirzepatide (Mounjaro®).

As of the time of writing, retatrutide is not approved for use in the UK. It remains an investigational compound, developed by Eli Lilly and Company, and does not hold a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). It has not received a positive opinion from the European Medicines Agency (EMA), and no European Public Assessment Report (EPAR) exists for this medicine. Retatrutide therefore cannot be legally prescribed or dispensed outside of authorised clinical research settings.

The ongoing Phase 3 programme — known as the TRIUMPH trials — is evaluating retatrutide across a broader population, including individuals with obesity, type 2 diabetes, and cardiovascular risk factors.^[2] Details of individual studies are registered on ClinicalTrials.gov. Results from these trials will form the basis of any future regulatory submission. If approved, the MHRA would assess the benefit–risk profile independently for the UK market, and NICE would subsequently evaluate cost-effectiveness before recommending NHS commissioning.

Given significant public and clinical interest in newer weight management therapies, patients should be aware of the risks associated with unregulated access. Retatrutide is not currently available through legitimate UK pharmacies or private clinics, and any product marketed as such should be treated with extreme caution. The MHRA actively monitors and takes enforcement action against the supply of unlicensed and falsified medicines. Guidance on the risks of buying medicines online is available at gov.uk/mhra.

For those seeking weight management support now, approved options in the UK include:

• Orlistat — available on NHS prescription and over the counter; see the NHS medicines page and the EMC SmPC for full prescribing information

• Semaglutide (Wegovy®) — approved by the MHRA and recommended by NICE under specific criteria (NICE TA875); see the EMC SmPC and NHS Wegovy page^[13]

• Tirzepatide (Mounjaro®) — approved by the MHRA with NICE guidance in place (NICE TA924); see the EMC SmPC and NHS Mounjaro page^[14]

Patients are encouraged to discuss their options with a GP, who can refer to tier 2, tier 3, or tier 4 specialist weight management services as appropriate (in line with NICE CG189 and local commissioning arrangements). Those interested in participating in clinical trials involving retatrutide or other investigational agents can search for UK studies via the NIHR 'Be Part of Research' portal at bepartofresearch.nihr.ac.uk.

Frequently Asked Questions